4 news items
KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTS
KZIA
1 May 24
selective small molecule VEGFR3 tyrosine kinase inhibitor targeting tumour angiogenesis. Unlike traditional angiokinase inhibitors, we believe based
Why Byrna Technologies Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
ACB
AGS
AIH
5 Apr 24
coverage on Ardelyx with an Outperform rating and announced a price target of $14.
Yatsen Holding Limited
Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases
KZIA
21 Mar 24
, which lead to the overactivation of the mTOR pathway. Paxalisib is an oral dual inhibitor targeting both PI3K and mTOR within this pathway
Kazia announces presentation of new data at AACR Annual Meeting
KZIA
13 Mar 24
Abstract CT088 / 15: EVT801, a novel selective VEGFR-3 inhibitor targeting tumor
- Prev
- 1
- Next